According to the President of Moderna Therapeutics company Dr. Stephen Hoge, the company has received fast-track approval from US Food and Drug Administration (FDA) for its vaccine candidate, mRNA-1273. It is days after Food and Drug Administration gave the company green light to proceed to phase two of clinical trials.
The company is also planing to start the last phase (3) at the summer. This means that the company is allowed to curry out it’s activities till the final data is collected and analysed for approval. According to Hoge, validation is an important exercise to FDA. “It’s validation that the FDA believes this is a very credible exercise”.
According to Hog, the company is Planning on mass production should their vaccine be Approved. The company has also plans to supply tens of millions of doses by the end of the year to prove it’s ability to avil the vaccine.
“We have not hit major speed bumps or road blocks, so it’s been good so far, but now as the data develops, we need to show that we can manufacture at scale, and we’re doing all we can to scale up to supply tens of millions of doses by the end of this year”.
Moderna’s vaccine relies on a new technology. The technology is based on the mRNA of the virus. The technology works in a way that fragments of the viral genetic material are injected into the body, later they stimulates and boost the body’s immune system to fight coronavirus disease 2019 (COVID-19).
There is currently no proven vaccine or medicine for COVID-19 according to WHO. There are 8 known vaccines globally that have reached human trial. Experts believe that there is need to have multiple vaccines to meet global demand to immunize and protect as many people as possible.